Tumor vaccines have been designed to target oncogenes, specifically c-myc, which is over expressed in 80% of CRC; vaccination resulted in generation of CD4+ and CD8+ T cells that infiltrated the tumor site (Williams et al., 2008). This evidence concerns the gene CD8A and neoplasm.